Third-Generation EGFR Inhibitors Show Inconclusive Efficacy in Uncommon Lung Cancer Mutations
A genotype-stratified systematic review indicates that third-generation EGFR inhibitors do not confer a uniform efficacy advantage across uncommon lung cancer ...

